Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Alumis and Acelyrin have agreed to merge in an all-stock deal, creating a late-stage biopharmaceutical company focused on ...

Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

NASDAQ:ALMS opened at $4.82 on Tuesday. Alumis has a 1-year low of $4.74 and a 1-year high of $13.53. The company has a 50-day moving average of $7.80 and a 200 day moving average of $10.19.

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...